<DOC>
	<DOCNO>NCT01871649</DOCNO>
	<brief_summary>The investigator perform 22-week randomize , double-blind , placebo-controlled trial golimumab + methotrexate ( MTX ) versus methotrexate alone methotrexate-naïve patient Psoriatic Arthritis ( PsA ) . Afterwards , 28 week open label phase methotrexate alone start . Golimumab discontinue . Hypotheses : First , investigator hypothesize initiation combination therapy golimumab + MTX safe superior MTX alone MTX-naïve PsA patient , assessed percentage patient achieve Disease Activity Score ( investigator hypothesize patient early combination treatment respond ( accord Disease Activity Score ( DAS ) , American college Rheumatology ( ACR ) , Psoriatic Arthritis Response Criteria ( PsARC ) response ) achieve state Low Disease Activity ( LDA ) Minimal Disease Activity ( MDA ) patient MTX alone . Third , investigator hypothesize significant proportion patient continue benefit early aggressive treatment initiation even stop golimumab treatment .</brief_summary>
	<brief_title>Initial Treatment With Golimumab Early PsA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Prior study procedure , voluntary write informed consent must obtain , nature purpose study explain Patients 18 70 year age time consent Patients must diagnosis PsA accord Classification psoriatic Arthritis ( CASPAR ) classification criterion ( see Appendix 1 ) . The patient must active disease define 3 swollen 3 tender joint . The use stable dose concomitant nonsteroidal antiinflammatory drug ( NSAIDs ) and/or corticosteroid allow . The dose corticosteroid exceed prednisone equivalent 10 mg/day must stable least 4 week prior baseline . The dose concomitant NSAIDs corticosteroid keep stable whole study period . Patients consider generally good health base upon result medical history , physical examination , laboratory profile , chest Xray electrocardiography ( ECG ) . Patient concomitant rheumatic condition PsA Positivity rheumatoid factor ( RF ) anticyclic citrullinated peptide ( anti CCP ) antibody ( ACPA ) Current previous use methotrexate Current use Disease Modifying Antirheumatic drug ( DMARDs ) ( sulphasalazine leflunomide ) . Prior use DMARDs ( sulphasalazine leflunomide ) within 3 month baseline . Current previous use biologicals , include Tumor Necrosis Factor ( TNF ) block therapy Patient active tuberculosis . A purified protein derivative ( PPD ) skin test chest Xray screen negative ( case latent tuberculosis , patient may enter study prophylaxis isoniazide begin prior administration study medication ) . If patient adequately treated tuberculosis past , he/she may enter trial . Patient receive intraarticular injection corticosteroid within 4 week prior baseline . Patient malignancy ( basal cell carcinoma skin ) past 5 year Patients recent history ( persistent ) infection require hospitalization antibiotic treatment within 4 week baseline Patient significant history cardiac , pulmonary , renal ( glomerular filtration rate &lt; 40ml/min ) , hepatic ( liver cirrhosis ) , hematological , neurological , metabolic disease may affect his/her participation study . This decided opinion investigator . All female childbearing potential must use appropriate contraception , postmenopausal surgically sterile . A urine pregnancytest betahuman chorion gonadotropin ( BetaHCG ) perform screen negative . Subject pregnant breastfeed woman Liver disease liver injury indicate abnormal liver function test Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , gammaglutamyl transpeptidase ( GGT ) , alkaline phosphatase , serum bilirubin . The Investigator guide follow criterion : Any single parameter may exceed 2 x upper limit normal ( ULN ) . A single parameter elevate include 2 x ULN rechecked elevation level find clinically relevant accord physician , least prior enrolment . Patient , opinion investigator , unable comply requirement study protocol unsuitable study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>psoriatic arthritis</keyword>
	<keyword>golimumab</keyword>
	<keyword>methotrexate</keyword>
	<keyword>minimal disease activity</keyword>
	<keyword>safety</keyword>
	<keyword>withdrawal</keyword>
</DOC>